Fig. 6: Silencing of Creb5 in exacerbation models results in a profound decrease in inflammation, AHR, and mucus hypersecretion. | Mucosal Immunology

Fig. 6: Silencing of Creb5 in exacerbation models results in a profound decrease in inflammation, AHR, and mucus hypersecretion.

From: Single-cell RNA transcriptomic analysis identifies Creb5 and CD11b-DCs as regulator of asthma exacerbations

Fig. 6

a Fold-change expression of Creb5 determined by qPCR analysis in mouse lungs relative to HPRT. b Measurement of airways resistance determined using flexivent lung-function platform, in response to incremental doses of nebulized methacholine represented as a percentage increase over baseline (PBS only) readings. c Differential counts of immune cells isolated from mouse bronchoalveolar lavage fluid (BALF) using light microscopy, represented as cells per milliliter. d Levels of mucus hypersecretion (MSCs) or eosinophil infiltration were assessed and scorings for histopathology (inflammatory infiltrates) were performed on the lung sections. e Representative histological pictures of AB-PAS stained mouse lung sections. Values are represented as mean ± SEM, n = 4–6. #Designates significant differences compared to both SAL and siRNA treated groups (#p < 0.05). HPF represents high power field.

Back to article page